TCRT News and Press, Alaunos Therapeutics Inc. From 11/13/23

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Alaunos Therapeutics Inc. (TCRT) is expected to report $-0.03 for Q3 2023

2023-08-15 07:16:32 ET More on Alaunos Alaunos slips 17% on Phase 1 data for cancer cell therapy Alaunos Therapeutics upgraded to buy at Wainwright on multiple catalysts Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology Alaunos &#...

TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...

HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...

2023-05-26 15:36:17 ET Alaunos Therapeutics ( NASDAQ: TCRT ) fell ~17% on Friday as investors reacted to data from a Phase 1/2 trial for its T-cell receptor (TCR) cell therapy candidate in patients with solid tumors harboring KRAS or TP53 genetic mutations. As of Feb. 2023, ...

TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in perip...

2023-05-10 15:40:23 ET Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Conference Call May 10, 2023 09:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President of Research & Deve...

2023-05-10 07:09:24 ET Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q1 GAAP EPS of -$0.04 in-line. As of March 31, 2023, Alaunos had approximately $37.4 million in cash balances, which included restricted cash of approximately $13.9 million. Based on current op...

Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended exclusive licensing agreement wit...